mABTree Biologics is a biotech company based in Basel, Switzerland, focused on developing affordable, innovative monoclonal antibody therapies for hematological cancers, such as myeloproliferative neoplasms (MPNs), and autoimmune diseases. Founded in 2019, mABTree aims to make cutting-edge immunotherapies more accessible to patients worldwide. Our lead product, MT-0002, is a fully human antibody targeting a unique tumor marker and has shown promising preclinical results, including tumor reduction and depletion of mutant hematopoietic stem cells in MPN models. We are preparing for clinical trials and seeking partnerships and investments to accelerate development and potential regulatory approval by 2025, with a strategy for orphan drug status to expedite availability in underserved areas of oncology and hematology.
Company Details
- Employees
- 8
- Founded
- -
- Address
- Hochbergerstrasse 60c, Basel,bs 4057,switzerland
- Industry
- Biotechnology
- Website
- mabtree.com
- Keywords
- Biosimilars, monoclonal Antibodies (mAbs), Recombinant Protein Therapeutics, Biologics, oncology, Hematology, Biotechnology.
- HQ
- Basel, BS
Mabtree Biologics Questions
Mabtree Biologics's website is mabtree.com
Mabtree Biologics's LinkedIn profile is https://ch.linkedin.com/company/mabtree-biologics
Mabtree Biologics has
8 employees.
View email and phone details for 8
employees at Mabtree Biologics.
Mabtree Biologics's industry is
Biotechnology
Mabtree Biologics's top competitors are
Document It,
Anaveon Ag,
Nxi Therapeutics Ag,
Shilpa Biologicals Private Limited,
Document It Llc,
Ridgeline Discovery,
Facultas Partners,
Mcbitss Gmbh,
Docit,
Versameb Ag.
Mabtree Biologics's categories are Biotechnology
Mabtree Biologics's founding year is 2019
